Biodegradable Lipids for the Delivery of Active Agents

U.S. Patent No. 11,246,933

Issued: February 15, 2022
Assignee: Alnylam Pharmaceuticals, Inc.
Title: Biodegradable Lipids for the Delivery of Active Agents
Focus: A class of biodegradable cationic lipids used to form lipid nanoparticles (LNPs) that can safely and efficiently deliver nucleic acids — especially fragile mRNA or RNAi molecules — into cells.

What This Patent Covers

This patent claims inventions around novel synthetic cationic lipids that:

Are designed with one or more biodegradable groups (e.g., ester linkages) in their structures.
Form lipid nanoparticle (LNP) systems that encapsulate therapeutic nucleic acids (such as mRNA) to protect them from degradation and enable efficient cellular delivery.
Are metabolized and cleared safely from the body after delivering their cargo, reducing toxicity seen with earlier non‑degradable lipids.

The innovation solved a key challenge in nucleic acid therapeutics: enabling safe, effective delivery of genetic medicines without harmful accumulation of the delivery materials themselves.

Why It’s Important

1. Core Delivery Technology for RNA Medicines

Alnylam’s patented biodegradable LNP technology is foundational in the field of RNA‑based therapeutics and vaccines, providing a way to get mRNA and similar molecules into human cells with good safety and efficacy profiles — something that is critical for both therapeutics and vaccines.

2. Linked to Major COVID‑19 Vaccine Disputes

Shortly after issuance in 2022, Alnylam filed lawsuits alleging that Pfizer and Moderna used this patented LNP technology in their COVID‑19 vaccines — products that have generated tens of billions in revenue — seeking compensation for unlicensed use.

3. Broad Platform Impact

The concept of biodegradable lipids for LNP formation supports not only vaccines but also RNAi and mRNA drugs alike. Since many cutting‑edge therapies (including several of Alnylam’s own products) rely on nucleic acid delivery, this patent underpins an infrastructure technology rather than a single drug — increasing its long‑term value.

4. Strategic Positioning in a Key Technology Space

Even though courts later questioned some infringement claims, the issuance of this patent positioned Alnylam as an IP owner in the critical RNA delivery landscape, giving it leverage in licensing discussions and partnerships in the rapidly growing field of RNA therapeutics and vaccines.

Summary

This patent protects a class of biodegradable lipids that help deliver mRNA and other RNA drugs into cells using lipid nanoparticles. Because successful delivery is one of the biggest technical hurdles in genetic medicines and vaccines, this intellectual property was (and remains) strategically important — so much so that Alnylam sued major vaccine makers over their use of similar delivery technology.

BioTech IP Review